期刊文献+

肝力克对肝纤维化大鼠肝组织ET-1mRNA、iNOSmRNA表达的影响 被引量:2

EFFCT OF GANLIKE ON ET-1 mRNA and iNOS mRNA EXPRESSION IN LIVER TISSUE OF RATS WITH HEPATIC FIBROSIS
下载PDF
导出
摘要 目的观察肝纤维化大鼠肝组织中ET-1mRNA、iNOSmRNA的表达及中药肝力克对其的影响,探讨肝力克治疗肝纤维化的可能作用机制。方法以40%CCl43ml/Kg体重皮下注射,连续9周,建立大鼠肝纤维化模型;将肝纤维化大鼠随机分为肝纤维化模型组、肝力克大、中和小剂量组,另设正常对照组。采用原位杂交法检测大鼠肝组织中ET-1和iNOS的mRNA表达情况。结果肝纤维化模型组大鼠肝组织ET-1mRNA、iNOSmRNA阳性表达均较正常对照组明显升高(P<0.01);应用肝力克能明显改善大鼠肝组织炎症活动度和纤维化程度,能明显下调肝纤维化大鼠肝组织iNOSmRNA表达,但对ET-1mRNA的表达无明显影响。结论ET-1、iNOS参与肝纤维化的发生发展,肝力克下调肝组织iNOSmRNA的表达可能是其抗肝纤维化作用的机理之一。 Objective:To observe the effect of ganlike on ET-1mRNA and iNOS mRNA expression in liver tissue of rats with hepatic fibrosis and discuss the mechanism.Mthods:the model of rats′ hepatic fibrosis were induced by subcutaneous injection of CCl_4, then the rats in the treatment groups were given the different dosages of ganlike by stomach-perfusion,the rats in the groups of the model and the normal were given saline,the mRNA expression of ET-1 and iNOS in all liver tissues was detected by in situ hybridization method.Results:the mRNA expression of ET-1 and iNOS in the hepatic fibrosis were significantly higher than that of the normal group(P<0.01),after treated with ganlike,the severity of inflammation and fibrosis were obviously improved,and the expression of iNOS mRNA in hepatic fibrosis was downregulated.the expression of ET-1 mRNA showed no significance.Conclusion:ET-1 and iNOS participate in the occurrence and development of hepatic fibrosis,ganlike may downregulate the mRNA expression of iNOS in the liver tissues of hepatic fibrosis,which may be a possible mechanism of anti-hepatic fibrosis.
机构地区 浙江省中医院
出处 《中国中医药科技》 CAS 2005年第5期277-278,280,共3页 Chinese Journal of Traditional Medical Science and Technology
基金 浙江省教育厅资助项目No.19990360 浙江省中医管理局资助项目No.2000Y03
  • 相关文献

参考文献14

二级参考文献21

  • 1程明亮,陆彤,吴亚云,刘琴,罗永芳,丁一生,李媛媛.α_1型基因工程干扰素和汉丹冲剂治疗早期肝硬化的组织学研究[J].中国中西医结合杂志,1995,15(5):300-301. 被引量:28
  • 2王泰龄,刘霞,高琳,赵静波,王宝恩.对慢性肝炎分类、分级分期的探讨[J].肝脏病杂志,1995,3(3):130-133. 被引量:21
  • 3程明亮,丁一生,罗永芳,田苗,吴君,罗天永,吴亚云,刘琴,杨京.汉丹必妥治疗慢性活动性肝炎肝纤维化的临床研究[J].中国中西医结合杂志,1996,16(7):431-432. 被引量:22
  • 4宋家武,李绍白,张文英.血府逐瘀汤抗大鼠肝纤维化作用的研究[J].中西医结合肝病杂志,1997,7(1):38-40. 被引量:27
  • 5[1]Marra F, Gentilini A, Pinzani M, et al. Phosphatidylinositol 3-Kinase is required for platelet-derived growth factor's actions on hepatic stellate cells. Gastroenterology, 1997,112:1297-1306.
  • 6[2]Rockey DC. The cellular pathogenesis of portal hypertension: Stellate cell contractility, endothelin and nitric oxide, Hepatology, 1997,25: 2-5.
  • 7[3]Friedman SL. Cytokines and fibrogenais. Semin liver Dis, 1999, 19:129-140.
  • 8[4]Tsukamoto H. Is inferleukin-10 antifibrogenic in chronic liver injury?Hepatology, 1998,28:1707-1709.
  • 9[5]Iredale JP, Murphy G, Hembry RM, et al. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1 (TIMP-1):implications for regulation of matrix degradation in liver. J Clin Invest, 1992,90: 282-287.
  • 10李诚秀 罗俊 李玲.汉丹肝乐对肝纤维化的治疗作用[J].中国医药学报,1998,13:199-201.

共引文献400

同被引文献32

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部